Evoke Pharma EBITDA Margin 2012-2025 | EVOK
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Evoke Pharma (EVOK) over the last 10 years. The current EBITDA margin for Evoke Pharma as of September 30, 2025 is .
| Evoke Pharma EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-09-30 | $0.01B | $-0.01B | -35.71% |
| 2025-06-30 | $0.01B | $-0.01B | -38.46% |
| 2025-03-31 | $0.01B | $0.00B | -33.33% |
| 2024-12-31 | $0.01B | $-0.01B | -45.45% |
| 2024-09-30 | $0.01B | $-0.01B | -60.00% |
| 2024-06-30 | $0.01B | $-0.01B | -77.78% |
| 2024-03-31 | $0.01B | $-0.01B | -114.29% |
| 2023-12-31 | $0.01B | $-0.01B | -133.33% |
| 2023-09-30 | $0.01B | $-0.01B | -160.00% |
| 2023-06-30 | $0.00B | $-0.01B | -200.00% |
| 2023-03-31 | $0.00B | $-0.01B | -266.67% |
| 2022-12-31 | $0.00B | $-0.01B | -400.00% |
| 2022-09-30 | $0.00B | $-0.01B | -800.00% |
| 2022-06-30 | $0.00B | $-0.01B | -800.00% |
| 2022-03-31 | $0.00B | $-0.01B | -800.00% |
| 2021-12-31 | $0.00B | $-0.01B | -900.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |